Detection of human cytomegalovirus cell-free DNA in pregnant women with symptomatically infected fetuses: proof-of-concept study.

IF 6.3 1区 医学 Q1 ACOUSTICS
Ultrasound in Obstetrics & Gynecology Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI:10.1002/uog.29199
B H W Faas, T Meuleman, G Astuti, A Reuss, K Stol, E A Sistermans, J Linthorst, E van Leeuwen, J Rahamat-Langendoen, F A Wilmink
{"title":"Detection of human cytomegalovirus cell-free DNA in pregnant women with symptomatically infected fetuses: proof-of-concept study.","authors":"B H W Faas, T Meuleman, G Astuti, A Reuss, K Stol, E A Sistermans, J Linthorst, E van Leeuwen, J Rahamat-Langendoen, F A Wilmink","doi":"10.1002/uog.29199","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the presence and levels of cytomegalovirus (CMV) cell-free DNA (cfDNA) fragments in women pregnant with a fetus with symptomatic congenital CMV (cCMV).</p><p><strong>Methods: </strong>The study comprised nine women whose fetuses were diagnosed with cCMV between June 2019 and July 2024 at 20 + 4 to 34 + 1 weeks' gestation (n = 8) or neonatally (n = 1) after primary or non-primary maternal infection. In eight women, cfDNA sequencing data from a single timepoint were analyzed, either retrospectively, on data generated from 11-13 weeks' gestation (n = 5) or prospectively, on data generated from 20-26 weeks' gestation (n = 3), upon the diagnosis of cCMV. In one woman (Case 6), CMV-cfDNA analysis was performed at four timepoints: at 12 + 5 weeks (routine non-invasive prenatal testing); 23 + 3 weeks (cCMV diagnosis); and 30 min and 12 h after termination of pregnancy (TOP) at 23 + 6 weeks.</p><p><strong>Results: </strong>CMV-cfDNA was detectable in all cases. Mostly low levels of CMV-cfDNA were observed in samples obtained at 11-13 weeks' gestation and consistently high levels of CMV-cfDNA were present in samples obtained at cCMV diagnosis. In Case 6, the level of maternal CMV-cfDNA decreased substantially in the samples tested after TOP, compared with samples obtained before TOP.</p><p><strong>Conclusions: </strong>Low levels of CMV-cfDNA detected between 11 and 13 weeks may be a biomarker for severe fetal cCMV. CMV-cfDNA analysis in the first trimester could be of added value in CMV screening, particularly for non-primary maternal infections that cannot be identified using other methods. However, as CMV-cfDNA is detectable in many pregnant women in the first trimester, further studies are needed to determine the predictive value of CMV-cfDNA as a biomarker for the development of severe fetal cCMV. High levels of CMV-cfDNA at fetal cCMV diagnosis and low levels directly after TOP suggest that the level of CMV-cfDNA in maternal plasma may not necessarily reflect an active maternal infection, but could indicate a placental infection. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.</p>","PeriodicalId":23454,"journal":{"name":"Ultrasound in Obstetrics & Gynecology","volume":" ","pages":"470-477"},"PeriodicalIF":6.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961104/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ultrasound in Obstetrics & Gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/uog.29199","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ACOUSTICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the presence and levels of cytomegalovirus (CMV) cell-free DNA (cfDNA) fragments in women pregnant with a fetus with symptomatic congenital CMV (cCMV).

Methods: The study comprised nine women whose fetuses were diagnosed with cCMV between June 2019 and July 2024 at 20 + 4 to 34 + 1 weeks' gestation (n = 8) or neonatally (n = 1) after primary or non-primary maternal infection. In eight women, cfDNA sequencing data from a single timepoint were analyzed, either retrospectively, on data generated from 11-13 weeks' gestation (n = 5) or prospectively, on data generated from 20-26 weeks' gestation (n = 3), upon the diagnosis of cCMV. In one woman (Case 6), CMV-cfDNA analysis was performed at four timepoints: at 12 + 5 weeks (routine non-invasive prenatal testing); 23 + 3 weeks (cCMV diagnosis); and 30 min and 12 h after termination of pregnancy (TOP) at 23 + 6 weeks.

Results: CMV-cfDNA was detectable in all cases. Mostly low levels of CMV-cfDNA were observed in samples obtained at 11-13 weeks' gestation and consistently high levels of CMV-cfDNA were present in samples obtained at cCMV diagnosis. In Case 6, the level of maternal CMV-cfDNA decreased substantially in the samples tested after TOP, compared with samples obtained before TOP.

Conclusions: Low levels of CMV-cfDNA detected between 11 and 13 weeks may be a biomarker for severe fetal cCMV. CMV-cfDNA analysis in the first trimester could be of added value in CMV screening, particularly for non-primary maternal infections that cannot be identified using other methods. However, as CMV-cfDNA is detectable in many pregnant women in the first trimester, further studies are needed to determine the predictive value of CMV-cfDNA as a biomarker for the development of severe fetal cCMV. High levels of CMV-cfDNA at fetal cCMV diagnosis and low levels directly after TOP suggest that the level of CMV-cfDNA in maternal plasma may not necessarily reflect an active maternal infection, but could indicate a placental infection. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

在有症状感染胎儿的孕妇中检测人巨细胞病毒无细胞DNA:概念验证研究
目的:探讨巨细胞病毒(CMV)游离DNA (cfDNA)片段在先天性巨细胞病毒(cCMV)孕妇体内的存在及水平。方法:该研究包括9名妇女,她们的胎儿在2019年6月至2024年7月期间被诊断为cCMV,妊娠20 + 4至34 + 1周(n = 8)或新生儿(n = 1),她们的胎儿在原发性或非原发性母体感染后被诊断为cCMV。在8名妇女中,对来自单一时间点的cfDNA测序数据进行分析,回顾性分析妊娠11-13周(n = 5)的数据,或前瞻性分析妊娠20-26周(n = 3)诊断为cCMV时的数据。在一名妇女(病例6)中,CMV-cfDNA分析在四个时间点进行:12 + 5周(常规无创产前检查);23 + 3周(cCMV诊断);23 + 6周终止妊娠后30min和12h (TOP)。结果:所有病例均检测到CMV-cfDNA。在妊娠11-13周获得的样本中观察到大多数低水平的CMV-cfDNA,而在cCMV诊断时获得的样本中持续存在高水平的CMV-cfDNA。在病例6中,与TOP前获得的样本相比,TOP后检测的样本中母体CMV-cfDNA水平显著下降。结论:在11 - 13周检测到低水平的CMV-cfDNA可能是严重胎儿cCMV的生物标志物。妊娠早期CMV- cfdna分析在CMV筛查中可能具有附加价值,特别是对于使用其他方法无法识别的非原发母体感染。然而,由于CMV-cfDNA在许多妊娠早期妇女中可检测到,CMV-cfDNA作为重度胎儿cCMV发展的生物标志物的预测价值有待进一步研究。胎儿cCMV诊断时CMV-cfDNA的高水平和TOP后的低水平提示母体血浆中CMV-cfDNA的水平不一定反映母体感染的活动性,但可能提示胎盘感染。©2025作者。妇产科学超声由John Wiley & Sons Ltd代表国际妇产科学超声学会出版。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.30
自引率
14.10%
发文量
891
审稿时长
1 months
期刊介绍: Ultrasound in Obstetrics & Gynecology (UOG) is the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) and is considered the foremost international peer-reviewed journal in the field. It publishes cutting-edge research that is highly relevant to clinical practice, which includes guidelines, expert commentaries, consensus statements, original articles, and systematic reviews. UOG is widely recognized and included in prominent abstract and indexing databases such as Index Medicus and Current Contents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信